Table 3.
Patient Demographics and Clinical Characteristics, Clinical Staging Procedures, and Pathology Review and TMA Immunophenotype
| Patient Demographics and Clinical Characteristics | No. of Patients |
||
|---|---|---|---|
| Uganda | Kenya | Total | |
| Patients screened | 144 | 113 | 257 |
| Patients with confirmed lymphoma | 140 | 112 | 252 |
| Patients with confirmed HIV serology | 65 | 84 | 149 |
| Patients registered | 23 | 29 | 52 |
| Patients treated and analyzed | 21 | 28 | 49 |
| Sex | |||
| Male | 7 | 13 | 20 |
| Female | 14 | 15 | 29 |
| Age, years | |||
| Median | 40 | 36.5 | 39 |
| Range | 18-57 | 26-64 | 18-64 |
| Performance status | |||
| 0 | 5 | 0 | 5 |
| 1 | 6 | 7 | 13 |
| 2 | 6 | 7 | 13 |
| 3 | 4 | 14 | 18 |
| Clinical stage | |||
| I | 2 | 4 | 6 |
| II | 2 | 7 | 9 |
| III | 2 | 2 | 4 |
| IV | 15 | 15 | 30 |
| A | 5 | 1 | 6 |
| B | 16 | 27 | 43 |
| CD4 count, cells/μL | |||
| Median | 123 | 206.5 | 198 |
| Range | 5-1,364 | 21-409 | 5-1,364 |
| Plasma HIV viral load, copies/mL | |||
| Median | 338,864 | 55,000 | 99,741 |
| Range | 831-11,700,000 | Undetectable-> 750,000 | Undetectable-11,700,000 |
| Antiretroviral therapy | |||
| None | 12 | 19 | 31 |
| Yes | 9 | 9 | 18 |
| Prior AIDS | |||
| Yes | 13 | 20 | 33 |
| No | 8 | 8 | 16 |
| Extranodal sites | |||
| ≤ 1 | 14 | 21 | 35 |
| > 1 | 7 | 7 | 14 |
| LDH, U/L (n = 35) | |||
| Median | 670.5 | 520 | 550 |
| Range | 282-2,375 | 124-1,338 | 124-2,375 |
| Prior thrush | |||
| No | 15 | 4 | 19 |
| Yes | 6 | 24 | 30 |
| Prior opportunistic infection | |||
| No | 8 | 8 | 16 |
| Yes | 13 | 20 | 33 |
| Albumin, g/L | |||
| Median | 3.2 | 3.2 | 3.2 |
| Range | 1.4-5.0 | 2.1-4.4 | 1.4-5.0 |
| Hematocrit, % | |||
| Median | 29.3 | 33.6 | 31.5 |
| Range | 14.3-42.0 | 19.4-43.1 | 14.3-43.1 |
| Body mass index, kg/m2 | |||
| Median | 18.8 | 25.5 | 21.1 |
| Range | 12-29.3 | 16.6-33.2 | 12-33.2 |
| Second-line mCHOP | |||
| No | 14 | 24 | 38 |
| Yes | 7 | 4 | 11 |
| Clinical staging procedures at baseline | |||
| Physical examination and tumor measurement | 21 | 28 | 49 |
| Bone marrow aspiration biopsy | 20 | 28 | 48 |
| Lumbar puncture for CSF cytology | 19 | 27 | 46 |
| Chest radiograph | 21 | 28 | 49 |
| Abdominal sonography | 21 | 28 | 49 |
| Computed tomography (site specified) | 1 (abdomen in India) | 2 (both neck) | 3 |
| Pathology review in East Africa (based on hematoxylin and eosin staining) | |||
| Tumor grade (n = 49) by Working Formulation | |||
| High grade | 16 | 15 | 31 |
| Intermediate to high grade | 1 | 0 | 1 |
| Intermediate grade | 4 | 12 | 16 |
| Low grade | 0 | 1 | 1 |
| Total | 21 | 28 | 49 |
| Pathology review in United States (review of histopathology slides and TMA) | |||
| Tumor grade (n = 33) by Working Formulation | |||
| High grade | 8 | 8 | 16 |
| Intermediate to high grade | 1 | 3 | 4 |
| Intermediate grade | 5 | 5 | 10 |
| Low to intermediate grade | 0 | 2 | 2 |
| Hodgkin's lymphoma | 0 | 1 | 1 |
| Total | 14 | 19 | 33 |
| TMA immunophenotype (n = 28) | |||
| B-cell lymphoma (not otherwise specified) | 0 | 4* | 4 |
| Diffuse large-cell lymphoma | 1† | 6‡ | 7 |
| Lymphoblastic lymphoma | 0 | 3§ | 3 |
| Burkitt's lymphoma | 1‖ | 2¶ | 3 |
| Plasmacytoid/plasmablastic lymphoma | 2# | 1** | 3 |
| Hodgkin's lymphoma | 0 | 1 | 1 |
| Insufficient number of intact cells (necrosis) | 5 | 2 | 7 |
| Total | 9 | 19 | 28 |
Abbreviations: TMA, tissue microarray; LDH, lactate dehydrogenase; mCHOP, dose-modified cyclophosphamide, doxorubicin, vincristine, and prednisone.
*
CD20+.
†
c-myc positive and CD20+.
‡
CD20+, n = 5; CD30+, n = 1.
§
TDT positive, n = 1; 2 CD79A+, n = 2.
‖
EBER positive, c-myc positive, and CD20+.
¶
EBER positive, n = 1; CD20+, n = 2.
#
EBER positive, c-myc positive/CD20+ (n = 1), CD30−, and CD79A−.
**
EBER positive, CD138+, MUM1 positive, TDT negative, and CD30–.